WILEX AG announces discontinuation of collaboration between its subsidiary Heidelberg Pharma and Roche

Munich, Germany, 12 August 2015 – WILEX AG (ISIN DE000A11QVV0 / WL6 / FSE) was informed today that Roche is discontinuing its partnership with the WILEX subsidiary Heidelberg Pharma GmbH with respect to their collaboration in the field of antibody-targeted amanitin conjugates (ATACs). The licence agreement was signed in 2013 and expanded in October 2014.

Roche has recently increased the focus of its oncology research strategy on cancer immunotherapies and deprioritised other internal and external oncology research programmes accordingly. Affected by this deprioritisation are the collaborative research efforts with Heidelberg Pharma, which in recent years have progressed well, on schedule, and in a mutually satisfactory manner.

Updated financial outlook for 2015

As a consequence of the termination of existing collaborative efforts to develop and identify novel antibody-targeted amanitin conjugates (ATACs), WILEX AG revised today its financial outlook for the current financial year. Due to lower sales revenues WILEX's cash reach is reduced from the end of the second quarter 2016 to the first quarter of 2016.

About WILEX and Heidelberg Pharma

WILEX AG is a biopharmaceutical company which has a ready for partnering portfolio of antibody-based diagnostic and therapeutic Phase III product candidates for the detection and targeted treatment of clear cell renal cell carcinoma. Research and development focus on the operations of its subsidiary Heidelberg Pharma GmbH in Ladenburg, which primarily advances the development of the innovative platform technology for antibody drug conjugates (ADC technology) and provides pre-clinical drug discovery and development services. WILEX is listed at the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol WL6. More information is available at http://www.wilex.com.

Suggested Articles

The money will fund early-phase development of a CD47x4-1BB bispecific that Kahr plans to test with Roche’s checkpoint inhibitor Tecentriq.

Bicycle will apply its discovery platform to multiple targets, putting itself in a position to pull in up to $1.7 billion in milestones.

Harvard University scientists are teaming up with the Guangzhou Institute of Respiratory Disease with a $115 million boost from China.